Medesis Pharma S.A. (ALMDP.PA)

3.15 €

-0.10 (-3.08%)
Rating:
Recommendation:
-
Symbol ALMDP.PA
Price 3.15 €
Beta 0.000
Volume Avg. 0.00M
Market Cap 13.751M
Shares () -
52 Week Range 2.86-7.16
1y Target Est -
DCF Unlevered ALMDP.PA DCF ->
DCF Levered ALMDP.PA LDCF ->
ROE -
ROA -
Operating Margin -
Debt / Equity 162.83% Buy
P/E -
P/B -
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades


Healthcare
Biotechnology
Paris

Medesis Pharma S.A., a clinical development stage biopharmaceutical company, engages in the development of orally administered molecule drug candidates to address unmet medical needs. Its products include NanoLithium (NP03), a clinical stage development product for the treatment of Alzheimer's disease; NanosiRNA DH for the treatment of Huntington's Disease; NU01 Plutonium and NU02 Cesium decorporation products for nuclear decorporation; a radioprotection drug to treat people irradiated following a civil or military nuclear accident (NP02 – NanoManganese); NanosiRNA COVID-19, an antiviral treatment solution for viral diseases; and NanosiRNA Resistant cancers and NanosiRNA Oncolytic virus for the treatment of oncology. The company was founded in 2003 and is based in Montpellier, France.